https://www.selleckchem.com/products/smifh2.html
The oncologic safety of sentinel lymph node biopsy (SLN alone for clinically node-positive (cN1-2) patients who convert to pathologic node-negativity (ypN after neoadjuvant chemotherapy (NAC) is not well established. This study retrospectively identified 244 consecutive patients with a diagnosis of cT1-3cN0-2 breast cancer who underwent NAC followed by SLNB at the authors' institution between 2013 and 2018. The patients were categorized as clinically node-negative (cN or cN1-2 before the onset of NAC, and the Kaplan-Meier method wa
Like
Comment
Share
